Kepler Cheuvreux Suisse SA Buys New Stake in Amgen Inc. $AMGN

Kepler Cheuvreux Suisse SA bought a new position in Amgen Inc. (NASDAQ:AMGN) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 2,462 shares of the medical research company’s stock, valued at approximately $866,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AMGN. High Note Wealth LLC grew its position in shares of Amgen by 5.8% in the fourth quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock valued at $166,000 after purchasing an additional 28 shares during the last quarter. TAGStone Capital Inc. lifted its position in shares of Amgen by 0.7% during the 4th quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock worth $1,351,000 after purchasing an additional 28 shares during the last quarter. Verus Capital Partners LLC boosted its stake in Amgen by 2.3% during the 4th quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock valued at $403,000 after purchasing an additional 28 shares during the period. Destination Wealth Management grew its holdings in Amgen by 2.1% in the 4th quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock valued at $456,000 after buying an additional 29 shares during the last quarter. Finally, Breakwater Capital Group grew its holdings in Amgen by 1.4% in the 1st quarter. Breakwater Capital Group now owns 2,039 shares of the medical research company’s stock valued at $717,000 after buying an additional 29 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Transactions at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.85% of the stock is owned by company insiders.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $374.15 on Monday. Amgen Inc. has a 1-year low of $269.77 and a 1-year high of $391.29. The firm has a market capitalization of $201.93 billion, a PE ratio of 26.04, a PEG ratio of 3.68 and a beta of 0.41. The business’s 50 day moving average is $342.43 and its 200-day moving average is $348.09. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the company posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Sell-side analysts predict that Amgen Inc. will post 22.39 earnings per share for the current year.

Analyst Ratings Changes

AMGN has been the subject of a number of research analyst reports. Jefferies Financial Group began coverage on Amgen in a report on Tuesday, March 10th. They set a “hold” rating and a $350.00 price target for the company. Wells Fargo & Company raised their price objective on shares of Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a research note on Thursday, March 19th. Truist Financial boosted their target price on shares of Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a research report on Friday, May 1st. Weiss Ratings reiterated a “buy (b)” rating on shares of Amgen in a research note on Thursday, June 18th. Finally, Wall Street Zen downgraded shares of Amgen from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $355.50.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.